Recent Price Movement and Market Context
On 8 December 2025, Brooks Laboratories’ stock recorded an intraday low of Rs.95.55, representing a fall of 3.92% on the day. This decline contributed to an eight-day losing streak, during which the stock’s cumulative return was negative by 8.84%. The day’s performance also showed the stock underperforming its sector by 2.41%, indicating relative weakness compared to its peers.
The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests a sustained downward momentum over multiple time frames.
Meanwhile, the broader market, represented by the Sensex, experienced a decline of 0.38% to close at 85,389.67 points, after opening flat. Despite this, the Sensex remains close to its 52-week high of 86,159.02, trading above its 50-day and 200-day moving averages, signalling a generally bullish trend in the wider market.
Long-Term Performance and Valuation Metrics
Over the past year, Brooks Laboratories has recorded a total return of -30.44%, contrasting with the Sensex’s positive return of 4.52% over the same period. The stock’s 52-week high was Rs.202.80, highlighting the extent of the recent price decline.
From a fundamental perspective, the company’s long-term financial indicators show modest growth and limited profitability. The average Return on Equity (ROE) stands at 2.42%, which is relatively low for the Pharmaceuticals & Biotechnology sector. Net sales have grown at an annual rate of approximately 4.36% over the last five years, indicating slow expansion.
Debt servicing capacity appears constrained, with an average EBIT to interest ratio of -3.69, suggesting challenges in covering interest expenses from operating earnings. The company’s valuation metrics include a Price to Book Value ratio of 2.5, which is considered elevated relative to its historical averages and peer group valuations.
Just announced: This Small Cap from Tyres & Allied with precise target price is our pick for the week. Get the pre-market insights that informed this selection!
- - Just announced pick
- - Pre-market insights shared
- - Tyres & Allied weekly focus
Profitability and Growth Trends
Despite the stock’s price decline, Brooks Laboratories has reported notable growth in profits and sales in recent quarters. The company’s profits have risen by 170.3% over the past year, a significant increase relative to its share price movement. The PEG ratio stands at 0.1, reflecting the relationship between price, earnings growth, and valuation.
Net sales for the latest six-month period reached Rs.48.96 crores, growing at a rate of 26.45%. Additionally, the company declared positive results for four consecutive quarters, with operating cash flow for the year recorded at Rs.2.63 crores. The Profit Before Tax excluding other income for the latest quarter was Rs.7.59 crores, showing a growth rate of 2563.2% compared to the previous four-quarter average.
Comparative Performance and Sector Positioning
Brooks Laboratories has consistently underperformed against the BSE500 benchmark over the last three years. Alongside the negative return of 30.44% in the past year, the stock has lagged behind its sector and broader market indices in each of the last three annual periods.
The Pharmaceuticals & Biotechnology sector itself has shown mixed performance, with Brooks Laboratories’ relative underperformance highlighting specific company-level factors impacting its share price.
Brooks Laboratories or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Shareholding and Corporate Structure
The majority ownership of Brooks Laboratories remains with its promoters, maintaining a concentrated shareholding structure. This ownership pattern is typical for many companies in the Pharmaceuticals & Biotechnology sector, where promoter influence often guides strategic decisions.
While the company has demonstrated some positive quarterly results and growth in sales and profits, the stock’s recent price trajectory reflects a cautious market stance amid broader valuation and performance considerations.
Summary of Key Price and Performance Data
Brooks Laboratories’ current share price of Rs.95.55 represents a significant decline from its 52-week high of Rs.202.80. The stock’s downward trend over the past eight trading sessions, combined with its position below all major moving averages, underscores the prevailing market sentiment.
In contrast, the Sensex remains near its 52-week high and trades above key moving averages, highlighting a divergence between the broader market and this particular stock’s performance.
Conclusion
The fall of Brooks Laboratories to its 52-week low is a reflection of multiple factors, including subdued long-term growth metrics, valuation considerations, and recent price momentum. While the company has reported positive quarterly results and profit growth, these have not translated into upward price movement in the stock over the recent period. Investors and market participants continue to monitor the stock’s performance within the context of sector trends and broader market conditions.
Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
